196194-58-8

Basic information

• Product Name: 4-CHLORO-2,6-DIFLUOROBENZOIC ACID
• Synonyms: RARECHEM AL BE 1307;4-CHLORO-2,6-DIFLUOROBENZOIC ACID
• CAS NO: 196194-58-8
• Molecular Formula: C₇H₃ClF₂O₂
• Molecular Weight: 192.55
• Mol File: 196194-58-8.mol

Chemical Properties

• Melting Point: 183-186℃
• Boiling Point: 255 °C at 760 mmHg
• Flash Point: 108 °C
• Appearance: /
• Density: 1.573g/cm³
• Vapor Pressure: 0.00866mmHg at 25°C
• Refractive Index: 1.534
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 4-CHLORO-2,6-DIFLUOROBENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CHLORO-2,6-DIFLUOROBENZOIC ACID(196194-58-8)
• EPA Substance Registry System: 4-CHLORO-2,6-DIFLUOROBENZOIC ACID(196194-58-8)

Safety Data

• Hazardous Substances Data: 196194-58-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-Chloro-2,6-difluorobenzoic acid is used as a reactant for the preparation of substituted heterobicyclic derivatives. These derivatives are utilized as inhibitors of Bruton's tyrosine kinase (BTK), which plays a crucial role in the regulation of B-cell development and function. Inhibition of BTK has shown promise in the treatment of various B-cell malignancies and autoimmune diseases.
In the context of the pharmaceutical industry, 4-Chloro-2,6-difluorobenzoic acid serves as a key building block in the synthesis of novel BTK inhibitors, which can be further developed into potential therapeutic agents for conditions such as chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma, and rheumatoid arthritis.
Additionally, due to its unique chemical structure, 4-Chloro-2,6-difluorobenzoic acid may also find applications in other areas of the chemical and materials science industries, such as in the development of new polymers, dyes, or other specialty chemicals.

InChI:InChI=1/C7H3ClF2O2/c8-3-1-4(9)6(7(11)12)5(10)2-3/h1-2H,(H,11,12)

Upstream product

• 154314-62-2 4-amino-2,6-difluorobenzoic acid 
• 124-38-9 carbon dioxide 
• 1435-43-4 1-chloro-3,5-difluorobenzene 

Downstream Products

• 1110663-16-5 4-chloro-2,6-difluoro-N-methyl-N-methoxybenzamide 
• 272104-45-7 C₇H₂Cl₂F₂O 
• 773134-12-6 4-chloro-2,6-difluorobenzoic acid methyl ester 
• 1472038-62-2 8-cyclopropyl-6-fluoro-2,3,4,5-tetrahydro-1,4-benzoxazepin-5-one 

Relevant articles and documents

FUSED BICYCLIC COMPOUND

The present invention provides a novel fused bicyclic compound having an affinity to a receptor of mineral corticoid (MR), shown by the formula [I]: wherein the ring A is a benzene ring having a substituent R1, fused to an adjacent 6-membered h

Quinazoline derivatives as VEGF inhibitors

The invention relates to quinazoline derivatives of formula (I) STR1wherein: Z represents --O--, --NH-- or --S--; m is an integer from 1 to 5; R 1 represents hydrogen, hydroxy, halogeno, nitro, trifluorometlyl, cyano, C 1-3 alkyl, C 1-3 alkoxy, C 1-3 alkylthio or NR 5 R 6 (wherein R 5 and R 6, which may be the same or different, each represents hydrogen or C 1-3 alkyl); R 2 represents hydrogen, hydroxy, halogeno, methoxy, amino, or nitro; R 3 represents hydroxy, halogeno, C 1-3 alkyl, C 1-3 alkoxy, C 1-3 alkanoyloxy, trifluoromethyl, cyano, amino or nitro; X 1 represents --O--, --CH 2 --, --S--, --SO--, SO 2 --, --NR 6 --, NR 8 CO--, --CONR 9 --SO 2 NR 10 -- or --NR 11 SO 2 --, (wherein R 7, R 8, R 9, R 10 and R 11 each represents C 1-3 alkyl, C 1-3 alkoxyC 2-3 alkyl); R 4 represents a group which is alkenyl, alkynyl or optionally substituted alkyl, which alkyl group may contain a heteroatom linking group, which alkenyl, alkynyl or alkyl group may carry a terminal optionally substituted 5 or 6 membered saturated carbocylic or heterocyclic group; and salts thereof, processes for their preparation, pharmaceutical compositions containing a compound of formula (I) or a pharmaceutically acceptable salt thereof as active ingredient the compounds of formula (I) and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.